Cohance Lifesciences has appointed industry veteran Abhimanyu Ojha as its Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026. Ojha joins with over two decades of leadership experience across major pharmaceutical firms including Intas, Viatris, and Sun Pharma. The board has also updated its regulatory disclosure policy to reflect the new leadership team responsible for material event reporting.
Cohance Lifesciences Appoints Abhimanyu Ojha as CFO
Abhimanyu Ojha appointed as Chief Financial Officer and KMP effective October 12, 2026.
Company updates regulatory disclosure policy to include new CFO in authorized personnel list.
Reader Takeaway: Leadership transition strengthens financial oversight with experienced pharma veteran; standard governance update for regulatory compliance.
What just happened
Cohance Lifesciences Ltd announced the appointment of Mr. Abhimanyu Ojha as its new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The board approved this decision during its meeting on October 9, 2026, acting on the recommendation of the Nomination and Remuneration Committee. The appointment takes effect on October 12, 2026.
Why this matters
As a designated KMP, the CFO plays a critical role in corporate governance and financial reporting. Consequently, the company has updated its policy for determining material events and disclosures under SEBI regulations. The new authorized team for regulatory oversight includes Mr. Umang Vohra (Chairman & Group CEO), Mr. Abhimanyu Ojha (CFO), and Mr. Sisir K Mishra (Company Secretary & Compliance Officer).
Background of the New CFO
Mr. Ojha brings over 20 years of expertise in the pharmaceutical and healthcare sectors. His previous leadership stints include serving as Global CFO & President Finance at Intas Pharmaceuticals, alongside senior roles at Viatris (formerly Mylan), Sun Pharmaceuticals, and Ranbaxy Laboratories. This depth of experience is expected to bolster the company’s financial strategy and regulatory adherence.
What to track next
Investors should note the change in authorized signatories for material disclosures. Future financial communications and regulatory filings will now reflect this updated leadership composition.